ESMO 2008 - GlaxoSmithKline to present encouraging new data supporting late stage development programme
- Newly integrated ‘GSK Oncology’ Research and Development unit announced
London, UK - At the 33rd meeting of the European Society of Medical Oncology (ESMO) Stockholm, Sweden, GlaxoSmithKline (GSK) Oncology will present exciting new data for Tyverb® (lapatinib) and pazopanib. These new data form the foundation of Phase III development plans for these molecules across a variety of tumours including Head and Neck, Ovarian, Lung, and Soft Tissue Sarcoma.
GSK will also present data for the anti-emetic neurokinin-1 receptor antagonist, Zunrisa™ (casopitant); the oxidative stress inducer, elesclomol, for metastatic melanoma and the antigen-specific cancer immunotherapeutic, MAGE-A3 ASCI for non-small cell lung cancer and metastatic melanoma.
These data represent a significant level of growth within GSK’s oncology portfolio - demonstrating the Company’s commitment to oncology and the strength of its late stage pipeline
Newly Integrated ‘GSK Oncology’
Today, GSK also announced the formation of a newly integrated Oncology Research and Development Organisation. GSK Oncology brings together small discovery units (DPUs) within the existing CEDD, and a highly specialised drug development group to create a dedicated oncology research and development organisation, led by Paolo Paoletti, M.D., Senior Vice President Oncology Research and Development.
“GSK has designed this new organisation to help us increase the breadth and depth of our core oncology knowledge, in order to ultimately deliver more innovative medicines that enhance cancer patients’ lives”, said Paoletti. “By creating an end-to-end R&D unit we are able to capture the many synergies that exist between discovery and development in oncology. The application of translational medicine will bring about significant enhancements to the R&D group via the ‘bench to bed’ connection - the constant loop and flow of information from early to late stage development, and vice-versa.”
“The newly formed GSK R&D Oncology Unit is directly aligned with our R&D strategy to deliver more products of value, and will help us increase our efforts towards personalised medicine in oncology,” said Moncef Slaoui, Chairman, Research and Development. “This dedicated unit will have the primary goals of identifying new targets and pathways, conducting innovative clinical research and cost-effectively increasing development capacity in order to deliver the unit’s large portfolio of medicines.”
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Notes to Editors
Key Oral Presentations:
Effect of lapatinib monotherapy on apoptosis and proliferation: results of a phase II randomised study in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) will be presented during the ESMO Head and Neck Cancer oral presentation session on Sunday 14, September, 10.00 – 10.15 CET
Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): A proof of concept study will be presented during the Chest Tumors oral presentation session on Monday 15, September, 10.45 – 11.00 CET
Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers; results of a phase II study will be presented during the ESMO Gynecological Cancer oral presentation session on Monday 15, September 10.45 – 11.00 CET
Pazopanib in patients with relapsed or refractory soft tissue sarcoma (STS); A phase II study from the EORTC STBSG (EORTC62043) will be presented during the ESMO Sarcoma Cancer oral presentation session on Monday 15, September, 14.30 – 14.45 CET
ESMO has selected two pazopanib abstracts for inclusion in their official ESMO press conference:
Results of a Phase II study of pazopanib in non-small cell lung cancer will be presented at the ESMO Press Breakfast, Saturday 13 September, 09.30 – 10.30 CET
Results of a Phase II study of pazopanib in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers will be presented at the ESMO Press Conference, Saturday 13 September, 12.30 – 13.30 CET
To access the latest GSK Oncology media materials, visit www.gskcancermedia.com
CEDD: Centre of Excellence for Drug Discovery
TYKERB® is a registered trademark of the GlaxoSmithKline group of companies in the United States.
TYVERB® is a registered trademark of the GlaxoSmithKline group of companies in Europe and is the proposed trade name in certain markets, pending regulatory approval.
Lapatinib is approved for sale in more than 55 countries including the United States, Europe, Australia, New Zealand, Switzerland, South Korea and certain countries in South America and the Middle East.
Registration dossiers for lapatinib have been filed in Canada and a number of countries in Asia, Latin America and the Middle East.
ZUNRISA™, the proposed trade name for casopitant, is a trademark of the GlaxoSmithKline group of companies.
Casopitant is not approved for marketing by any regulatory body in any country.
Pazopanib is not approved for marketing by any regulatory body in any country.
MAGE-A3 ASCI is not approved for marketing by any regulatory body in any country.
Elesclomol is not approved for marketing by any regulatory body in any country. Elesclomol is being developed under a global collaboration agreement between Synta Pharmaceuticals and GlaxoSmithKline.
This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ’Risk Factors’ in the ’Business Review’ in the company’ s Annual Report on Form 20-F for 2007.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.